gemcitabine plus carboplatin

DRUG3 trials

Conditions

Carcinoma, Non-Small-Cell LungNeoplasmsTriple Negative Breast Cancer

Phase 1

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

CompletedNCT02723955

GlaxoSmithKlineNeoplasms

Start: 2016-06-23End: 2023-07-05Updated: 2024-12-27

Phase 2

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

CompletedNCT01236716

Chinese Society of Lung CancerCarcinoma, Non-Small-Cell Lung

Start: 2010-11-30End: 2014-06-30Updated: 2014-08-06

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720

OncoSec Medical IncorporatedTriple Negative Breast Cancer

Start: 2018-10-11End: 2024-09-30Target: 65Updated: 2023-06-01

2024-02-1310 citations

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Cancer Research Communications2023-07-1914 citations

Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol

Radiology and Oncology2022-05-1022 citations

Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141)

Cancer Research2022-02-152 citations

Abstract P2-14-06: Durable responses with intratumoral electroporation of plasmid interleukin-12 plus pembrolizumab in patients with advanced triple-negative breast cancer: Cohort 1 update from KEYNOTE-890

Cancer Research2022-02-15

Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

Cancer Research2021-07-011 citations

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

Journal of Clinical Oncology2021-05-2031 citations

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2020-05-2017 citations

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.

Journal of Clinical Oncology2020-05-2010 citations

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

2019-02-0715 citations

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of Oncology2018-10-0111 citations

Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Cancer Research2017-07-017 citations

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2017-05-2011 citations

Abstract IA22: Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and antitumor response

Cancer Immunology Research2016-10-31

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

BMC Cancer2014-09-2011 citations

A phase II trial of first-line <i>nab</i>-paclitaxel/carboplatin versus gemcitabine/carboplatin in advanced squamous cell carcinoma of the lung (CTONG1002).

Journal of Clinical Oncology2014-05-204 citations

gemcitabine plus carboplatin

Sponsors

Conditions

Phase 1

Phase 2

Related Papers